OPKO Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on July 22, 2020, reporting events occurring on July 22 and July 23, 2020. The filing focuses on corporate governance changes, specifically the appointment of a new director and the promotion of an existing executive to multiple senior financial roles.
Key Financial Metrics
The filing does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly limited to Item 5.02 regarding personnel changes.
Material Changes
- Director Appointment: On July 23, 2020, the Board appointed Jon R. Cohen, M.D., as a new director. He will serve until the 2021 Annual Meeting of Stockholders. Dr. Cohen has served as Executive Chairman of the Company's subsidiary, BioReference Laboratories, Inc., since January 2019.
- Executive Promotions: On July 22, 2020, Rulfo Hernandez was appointed as Chief Accounting Officer, Treasurer, and Global Corporate Controller. He previously served as Corporate Controller since May 2014.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding the new appointments, the Company confirmed there were no compensatory plan arrangements entered into with Mr. Hernandez in connection with his new titles, and no material transactions involving Dr. Cohen requiring disclosure under Regulation S-K Item 404(a). Standard indemnification agreements were executed for both individuals.
Investor Verification Checklist
- Verify the effective dates of the appointments for Dr. Cohen and Mr. Hernandez.
- Review the Company's definitive proxy statement on Schedule 14A (filed April 29, 2020) for details on standard executive benefits applicable to Mr. Hernandez.
- Confirm the terms of the standard director and officer indemnification agreements referenced in the 2019 Form 10-K.
- Check for any subsequent filings regarding the 2021 Annual Meeting of Stockholders where Dr. Cohen's term will be addressed.